Speciality: Rheumatology
Description:
A warm welcome to all the medical professionals in this interesting session of efficacy and safety of JAK inhibitor drugs tofacitinib in rheumatoid arthritis. We have Dr. Sundeep Upadhyaya, Dr. Sonal Mehra, Dr. Chanchal Gera to lead the session.
Immunological pathways play a crucial role in rheumatic disease management. Managing rheumatoid arthritis often becomes difficult due to its rate of progression and associated health issues.
The webinar will help in gaining important insights on the efficacy and safety of JAK inhibiting drugs like tofacitinib in controlling rheumatoid arthritis. Tofacitinib inhibits the process of intracellular signaling from the receptor to the cellular nucleus and inhibits the inflammation process via inhibition of the Janus kinases.
Data from the clinical trials have suggested the use of JAK inhibitors like tofacitinib has much lower risk of infection or other side effects compared to TNF inhibitors. Learn more about the safety of tofacitinib from this session.
Therefore, listen to the webinar, grab the knowledge that is shared and follow HiDoc for more such interesting webinar sessions.
See More Webinars @ Hidoc Webinars
1.
Combo Therapy Boosts Early CML Response but Not Long Term
2.
PNH With Extravascular Hemolysis Approves Factor D Inhibitor.
3.
In a long-term comparison with adjuvant RT, salvage radiotherapy after prostateectomy is the most successful treatment.
4.
AI Breath Test IDs Cancers; More Grief for Prior Auth; Imatinib Discoverer Resigns
5.
Classifying childhood brain cancers by immune response may improve diagnostics and treatments
1.
Precision Oncology: Integrating Genomics and Data to Shape Cancer Care’s Future
2.
Decoding Hamartomas: Understanding Their Causes and Symptoms
3.
Understanding the Silent Threat: Unveiling Prostate Cancer Symptoms
4.
Battling Blood Cancers: Advances in HIV-Related Hematologic Malignancies in the ART Era
5.
Breaking Barriers: Innovative Approaches in Brain Tumor Treatment
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
Effect of Pablociclib in Endocrine Resistant Patients - A Panel Discussion
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Efficient Management of First line ALK-rearranged NSCLC
4.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
5.
Pazopanib: A Game-Changer in Managing Advanced Renal Cell Carcinoma
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation